In addition, suspected side effects can be reported directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app
16 Figure 3: Risk of OACs in patients on GLP-1s versus patients on insulin Conclusion GLP-1s, initially developed to help manage and treat diabetes and later used to treat obesity, are now showing significant potential to help prevent and treat CVD, mental health disorders, liver and kidney disorders, neurodegenerative disorders, addiction disorders, and cancer
In other words, not only might the drug get results like gastric bypass, it could substantially delay orfor people with less advanced arthritispossibly even eliminate the need for pricey and painful knee replacement
Bismuth subsalicylate (Pepto-Bismol) addresses broader stomach upset and helps ease hangover diarrhea use it cautiously with kidney disease or aspirin sensitivity
- - ( )
By twelve months, that number climbed to 22.4%
